menu
    • menu
    [{"orgOrder":0,"company":"PAREXEL International Corporation","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Rilvegostomig","moa":"PDCD1","graph1":"Oncology","graph2":"Phase I","graph3":"PAREXEL International Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PAREXEL International Corporation \/ PAREXEL International Corporation","highestDevelopmentStatusID":"6","companyTruncated":"PAREXEL International Corporation \/ PAREXEL International Corporation"},{"orgOrder":0,"company":"PAREXEL International Corporation","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"AZD0516","moa":"STEAP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PAREXEL International Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PAREXEL International Corporation \/ PAREXEL International Corporation","highestDevelopmentStatusID":"7","companyTruncated":"PAREXEL International Corporation \/ PAREXEL International Corporation"},{"orgOrder":0,"company":"PAREXEL International Corporation","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Laroprovstat","moa":"PCSK9","graph1":"Endocrinology","graph2":"Phase I","graph3":"PAREXEL International Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PAREXEL International Corporation \/ PAREXEL International Corporation","highestDevelopmentStatusID":"6","companyTruncated":"PAREXEL International Corporation \/ PAREXEL International Corporation"},{"orgOrder":0,"company":"PAREXEL International Corporation","sponsor":"Norgine","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Polyethylene Glycol 3350","moa":"PPA-gamma receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"PAREXEL International Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"PAREXEL International Corporation \/ PAREXEL International Corporation","highestDevelopmentStatusID":"10","companyTruncated":"PAREXEL International Corporation \/ PAREXEL International Corporation"},{"orgOrder":0,"company":"PAREXEL International Corporation","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"Glutamate [NMDA] receptor subunit epsilon 1","graph1":"Undisclosed","graph2":"Phase I","graph3":"PAREXEL International Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PAREXEL International Corporation \/ PAREXEL International Corporation","highestDevelopmentStatusID":"6","companyTruncated":"PAREXEL International Corporation \/ PAREXEL International Corporation"},{"orgOrder":0,"company":"PAREXEL International Corporation","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"AZD3974","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"PAREXEL International Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"PAREXEL International Corporation \/ PAREXEL International Corporation","highestDevelopmentStatusID":"6","companyTruncated":"PAREXEL International Corporation \/ PAREXEL International Corporation"},{"orgOrder":0,"company":"PAREXEL International Corporation","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Andexanet Alfa","moa":"Tissue factor pathway inhibitor | Apixaban | Rivaroxaban","graph1":"Undisclosed","graph2":"Phase III","graph3":"PAREXEL International Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PAREXEL International Corporation \/ PAREXEL International Corporation","highestDevelopmentStatusID":"10","companyTruncated":"PAREXEL International Corporation \/ PAREXEL International Corporation"}]

    Find Clinical Drug Pipeline Developments & Deals by PAREXEL International Corporation

    Menu

    PAREXEL International Corporation

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            PAREXEL International Corporation

                            U.S.A arrow
                            Biotech Showcase
                            Not Confirmed

                            PAREXEL International Corporation

                            U.S.A arrow
                            Biotech Showcase
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Andexanet Alfa,Rivaroxaban,Enoxaparin Sodium,Apixaban

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Hea...

                            Details : Andexanet Alfa is a protein drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            December 31, 2025

                            Lead Product(s) : Andexanet Alfa,Rivaroxaban,Enoxaparin Sodium,Apixaban

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            PAREXEL International Corporation

                            U.S.A arrow
                            Biotech Showcase
                            Not Confirmed

                            PAREXEL International Corporation

                            U.S.A arrow
                            Biotech Showcase
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AZD3974

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD3974 in Healthy Participants

                            Details : (AZD3974) is currently being evaluated in Phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 18, 2025

                            Lead Product(s) : AZD3974

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            PAREXEL International Corporation

                            U.S.A arrow
                            Biotech Showcase
                            Not Confirmed

                            PAREXEL International Corporation

                            U.S.A arrow
                            Biotech Showcase
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dextromethorphan,Capivasertib

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Dextromethorphan (CYP2D6 Sub...

                            Details : Dextromethorphan is a small molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 21, 2025

                            Lead Product(s) : Dextromethorphan,Capivasertib

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            PAREXEL International Corporation

                            U.S.A arrow
                            Biotech Showcase
                            Not Confirmed

                            PAREXEL International Corporation

                            U.S.A arrow
                            Biotech Showcase
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Polyethylene Glycol 3350,Ascorbic Acid,Potassium Chloride,Sodium Ascorbate,Sodium Chloride

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Recipient : Norgine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PLENVU vs Sodium Picosulfate for Bowel Cleansing in Children

                            Details : Plenvu (Polyethylene Glycol 3350) is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Gastrointestinal Diseases.

                            Product Name : Plenvu

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 20, 2025

                            Lead Product(s) : Polyethylene Glycol 3350,Ascorbic Acid,Potassium Chloride,Sodium Ascorbate,Sodium Chloride

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Recipient : Norgine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            PAREXEL International Corporation

                            U.S.A arrow
                            Biotech Showcase
                            Not Confirmed

                            PAREXEL International Corporation

                            U.S.A arrow
                            Biotech Showcase
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Laroprovstat,Paclitaxel,Cetuximab,Trastuzumab

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Recipient : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate the Effect of AZD0780 on Metformin Pharmacokinetics in Healthy Adult Volunteers Aged 18...

                            Details : Laroprovstat is a Miscellaneous drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Diabetes Mellitus, Type 2.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 14, 2025

                            Lead Product(s) : Laroprovstat,Paclitaxel,Cetuximab,Trastuzumab

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Recipient : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            PAREXEL International Corporation

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            PAREXEL International Corporation

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AZD0516,AZD9574

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

                            Details : AZD0516 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Prostatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            September 18, 2025

                            Lead Product(s) : AZD0516,AZD9574

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            PAREXEL International Corporation

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            PAREXEL International Corporation

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rilvegostomig,Hyaluronidase

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants Wit...

                            Details : Rilvegostomig is a Antibody, Unconjugated drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            September 08, 2025

                            Lead Product(s) : Rilvegostomig,Hyaluronidase

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.